نتائج البحث

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

• Authors : Bristol-Myers Squibb; Xiao X. Wei, MD, Sponsor Investigator

• Source: A Phase 2 Multicohort Study of Nivolumab in Combination With Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients With DNA

تفاصيل العنوان

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

• Authors : National Cancer Institute (NCI)

• Source: A Randomized Phase II Study of ADT + Abiraterone Versus ADT + Docetaxel + Abiraterone in Patients With Low

تفاصيل العنوان

Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial.

• Authors : Yang X; Department of Urology, Kidney and Urology Center, Pelvic Floor Disorders Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.; Chen H

Subjects: Androgen Antagonists*/Androgen Antagonists*/Androgen Antagonists*/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/administration & dosage ; Docetaxel*/Docetaxel*/Docetaxel*/administration & dosage

• Source: BMC cancer [BMC Cancer] 2022 Feb 16; Vol. 22 (1), pp. 177. Date of Electronic Publication: 2022 Feb 16.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

تفاصيل العنوان

A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients (ARASAFE)

• Authors : Bayer; Marc-Oliver Grimm, Prof. Dr. Marc-Oliver Grimm

• Source: A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week

تفاصيل العنوان

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

• Authors : Andrew J. Armstrong, MD, Professor of Medicine and Surgery

• Source: A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate

تفاصيل العنوان

Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC

• Authors : Hua Lixin, M.D.

• Source: A Prospective Randomized Controlled Study Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +

تفاصيل العنوان

Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in Patients With High Tumor Burden mHSPC: a Multicenter and Prospective Cohort Study

• Source: Efficacy and Safety of Apantamide Combined With Docetaxel and ADT vs. Apantamide Combined With ADT in

تفاصيل العنوان

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer (ACADEMIC)

• Source: ACADEMIC: A Randomized Phase II Clinical Trial of ADT Combined With Abiraterone or Docetaxel in Metastatic Hormone Sensitive Prostate

تفاصيل العنوان

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients

• Authors : LIU Sanhe; CUI Diansheng; JIA Quan'an

Subjects: docetaxel; adt; metastatic hormone-sensitive prostate cancer

• Source: Zhongliu Fangzhi Yanjiu, Vol 46, Iss 6, Pp 526-531 (2019)

تفاصيل العنوان

ADT Plus Abiraterone Remains the Best Approach.

• Authors : Dreicer, Robert

• Source: AUANews. Sep2018, Vol. 23 Issue 9, p10-12. 3p.

تفاصيل العنوان